Alzheimer's study looking for recruits

If you are at least 50 years of age and have a diagnosis of probably or mild-to-moderate Alzheimer's disease, then you may eligible to participate in a Phase II clinical study of resveratrol. The study is designed to determine the safety, tolerability and effectiveness of Resveratrol on cerebrospinal fluid and other biomarkers for the treatment of Alzheimer's. Derived from plants, resveratrol is found in its highest concentration in red wine and the skin of red grapes and a 2002 heart study showed that weekly and monthly intake of red wine was linked to a lower risk of dementia. Resveratrol has also been found to be beneficial for ocular health. Dr. Paul Krawitz developed Reziva which is made from French wine grapes and just one capsule of Reziva gives you as much resveratrol as 30 glasses of red wine. 120 people will be enrolled in the study and it will take place at about 26 sites across the United States. Approximately five participants will be enrolled at each site and the study will last up to 12 months and require up to 10 study visits. If you are interested in taking part in this study, please go to clinicaltrials.gov for more information.*